PPD deepens its Japanese focus with new joint venture leadership

Paul Colvin

PPD hired a general manager to help grow its Japan-focused joint venture with Shin Nippon Biomedical Laboratories, snagging a Parexel International ($PRXL) veteran as it works to expand its presence in a growing market for clinical development services.

Yasumasa Kurioka is on board as GM to help lead PPD-SNBL, launched earlier this year, reporting to joint venture CEO and PPD Vice President Paul Colvin. Kurioka spent 5 years at Parexel, serving as head of Japanese clinical operations, and previously held leadership positions at Eli Lilly ($LLY) and Novartis ($NVS).

At the joint venture, Kurioka is tasked with bringing "innovative operational strategies that will enable PPD-SNBL to use its extensive resources, long-term experience and local expertise to further meet its clients' needs in this important global market," Colvin said in a statement.

Under a deal closed in April, PPD merged its existing Japanese clinical development operation with SNBL's research division, creating a joint venture with offices in Tokyo, Osaka and Kagoshima. The American CRO holds a majority stake in the venture, and SNBL Chairman Ryoichi Nagata serves as its president. The combined entity employs about 400 people in the country, offering Phase I through IV services, the companies said.

The SNBL joint venture is among a series of deals PPD has used to expand its global capacity. Last year, the company partnered with the data collection experts at ERT and bought out the discovery-focused outfit X-Chem in an acquisition designed to bolster its early-stage expertise.

- read the statement

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.